[1]李莉.放射增敏剂研究概况[J].国际放射医学核医学杂志,2001,25(2):87-90.
　LI Li.Survey of research on radiation-sensitizing agents[J].International Journal of Radiation Medicine and Nuclear Medicine,2001,25(2):87-90.
点击复制

放射增敏剂研究概况(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
25
期数:
2001年第2期
页码:
87-90
栏目:
综述
出版日期:
1900-01-01

文章信息/Info

Title:
Survey of research on radiation-sensitizing agents
作者:
李莉
300192 天津, 中国医学科学院中国协和医科大学放射医学研究所
Author(s):
LI Li
Institute of Radiation Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300192, China
关键词:
放射增敏剂; 乏氧细胞毒性物; 一氧化氮供体; 血红蛋白别构效应物; 金属卟啉
Keywords:
radiation-sensitizing agents; hypoxic cytotoxins; nitric oxide donor agents; allosteric effectors of haemoglobin; metalloporphyrins
分类号:
R730.5
摘要:
肿瘤乏氧是导致放疗失败的一个重要原因,放射增敏剂由于能提高乏氧细胞对射线的敏感性而受到广泛重视。目前,放射增敏剂的研究包括传统硝基咪唑类化合物、乏氧细胞毒性物、一氧化氮供体、血红蛋白别构效应物和金属卟啉等,它们通过不同作用机制改善组织氧合状态或选择性杀死乏氧细胞,从而提高细胞对射线敏感性。由于肿瘤微环境极其复杂,尽管已合成了大量不同类型的化合物,但尚未发现真正能适用于临床的药物。
Abstract:
Hypoxia in solid tumors is a major problem for radiotherapy, so great interest has been given to the development of radiosensitizers which can enhance tissue response to radiation. Nowadays, research on radiosensitizers includes conventional nitroimidazoles, hypoxic cytotoxins, nitric oxide donor agents, allosteric effectors of haemoglobin, metalloporphyrins and so on. They can either increase oxygen delivery to the tumor or selectively kill the hypoxic cells. Though many compounds of different types have been synthesized, none of them can be used clinically because of the complexity of tumor microenviroment.

参考文献/References:

[1] Grigsby PW,Winter K,Wasserman TH,et al.Irradiation with or without misonidazole for patients with stages ⅢB and IV A carcinoma of the cervix:final results of RTOG 80-05[J].Int J Radiat Oncol Biol Phys,1999,44(3):513-517.
[2] Siim BG,Menke DR,Dorie MJ,et al.Tirapazamine-induced cytotoxicity and DN A damage in transplanted tumors:relationship to tumor hypoxia[J].Cancer Res,1997,57:2922-2928.
[3] Brown JM.The hypoxtc cell:a target for selective cancer therapy-eighteenth Bruce F.Cain Memorial Award lecture[J].Cancer Res,1999,59:5863-5870.
[4] Shulman LN,Busmell L,Riese N,et al.Phase I trial of the hypoxic cell cytotoxin tirapazamine with concurrent radiation therapy in the treatment of refractory solid tumors[J].Int J Radiat Oncol Biol Phys,1999,44(2):349-353.
[5] Lee D-J,Trotti A,Spencer S,et al.Concurrent tirapazamine and radiotherapy for advanced head and neck carcinomas:a Phase Ⅱ study[J].Int J Radiat Oncol Biol Phys,1998,42:811-815.
[6] Mitchell JB,Cook JA,Krishna MC,et al.Radlation sensitisation by nitric oxide releasing agents[J].Br J Cancer,1996,74(Suppl.27):S 181-S 184.
[7] Griffin RJ,Wakepeace CM,Hur W J,et al.Radiosensitization of hypoxic tumor cells in vitro by nitric oxide[J].Int J Radiat Oncol Biol Phys,1996,36:377-383.
[8] Verovski VN,Van den Berge DL,Soete GA,et al.Intrinsic radiosensitivity of human pancreatic tumour cells and the radiosensitising potency of the nitric oxide donor sodium nitroprusside[J].Br J Cancer,1996,74:1734-1742.
[9] Janssens M Y,Verovski VN,Van den Berge DL,et al.Radiosensitization of hypoxic tumour cells by S-nitroso-N-acetylpenicillamine implicates a bioreductive mechanism of nitric oxide generation[J].Br J Cancer,1999,79:1086-1089.
[10] Jordan BF,Misson P,Demeure R,et al.Changes in tumor oxygenation/perfusion induced by the NO donor,isosorbide dinitrate,in comparison with carbogen:monitoring by EPR and MRI[J].Int J Radiat Oncol Biol Phys,2000,48(2):565-570.
[11] Khandelwal SR,Kavanagh BD,Lin P-S,et al.RSR 13,an allosteric effector of haemoglobin,and carbogen radiosensitize FSaⅡ and SCCVⅡ tumours in C3H mice[J].Br J Cancer,1999,79:814-820.
[12] Teicher BA,Ara G,Emi Y,et al.RSR13:effects on tumor oxygenation and response to therapy[J].Drug Dev Res,1996,38:1-11.
[13] Kavanagh BD,Khandelwal SR,Schmidt-Ullrich RK,et al.A phase IB study to evaluate repeated daily intravenous doses of RSR13 administered to cancer patients receiving concurrent radiation therapy[J].Int J Radiat Oncol Biol Phys,1997,39:330S.
[14] Young SW,Qine F,Harriman A,et al.Gadolinium(Ⅲ) texaphyrin:a tumor selective radlation sensitizer that is detectable by MRI[J].Proc Natl Acad Sci USA,1996,93:6810-6615.
[15] Miller RA,Woodburn K,Fan Q,et al.In vivo animal studies with Gadolinium(Ⅲ) texaphyrin as a radiation enhancer[J].Int J Radiat Oncol Biol Phys,1999,45(4):981-989.
[16] Sessler JL,Miller RA.Texaphyrins:new drugs with diverse clinical applications in radiation and photodynamic therapy[J].Biochem Pharmacol,2000,59(7):733-739.
[17] Bernhard EJ,Mitchell JB,Deen D,et al.Re-evalnating gadolinium(Ⅲ)texaphyrin as a radiosensitizing agent[J].Cancer Res,2000,60(1),86-91.
[18] Lawrence TS,Eisbruch A,McGinn CJ,et al.Radiosensitization by gemcitabine[J].Oncology,1999,13(10 suppl.5):55-60.
[19] Ezekiel MP,Robert F,Meredith RF,et al.Phase I study of anti-epidermal growth factor receptor antibody c225 in combination with irradiation inpatients with advanced squamous cell carcinoma of the head and neck[J].Proc Am Soc Clin Oncol,1998,17:395a.
[20] Wouters BG,Brown JM.Cells at intermediate oxygen levels can be more important than the "hypoxicfraction" in determining tumor response to fractionated radiotherapy[J].Radiat Res,1997,147:541-550.

相似文献/References:

[1]李莉,李美佳.抗癌新药dFdC及其放射增敏效应[J].国际放射医学核医学杂志,1999,23(3):120.
[2]舒融,骆传环,胡壁.放射增敏剂研究进展[J].国际放射医学核医学杂志,1995,19(6):273.

备注/Memo

备注/Memo:
收稿日期:2000/12/14。
作者简介:李莉(1975-),女,湖北十堰人,中国医学科学院中国协和医科大学放射医学研究所博士研究生,主要从事肿瘤乏氧的研究。
更新日期/Last Update: 1900-01-01